Epidermal growth factor receptor (EGFR) and the mutant EGFRvIII are major focal points in
current concepts of targeted cancer therapy for glioblastoma multiforme (GBM), the most …

Glioblastoma is a particularly resilient cancer, and while therapies may be able to reach the
brain by crossing the blood–brain barrier, they then have to deal with a highly invasive tumor …

Glioblastoma multiforme (GBM) is the most common brain tumour and has the worst
prognosis. Epidermal growth factor receptor (EGFR) gene amplification, mutation and re …

Despite all of the progress in understanding its molecular biology and pathogenesis,
glioblastoma (GBM) is one of the most aggressive types of cancers, and without an efficient …

Glioblastoma, GBM, is the most frequent brain malignancy in adults. Patients with these
tumors survive only, approximately, one year after diagnosis and rarely survive beyond two …

The epidermal growth factor receptor (EGFR) is dysregulated in various tumour types such
as glioblastoma multiforme (GBM), breast cancer, ovarian carcinoma, non-small cell lung …

Nowadays, due to recent advances in molecular biology, the pathogenesis of glioblastoma
is better understood. For the newly diagnosed, the current standard of care is represented by …

Amplification of epidermal growth factor receptor (EGFR) and its active mutant EGFRvIII
occurs frequently in glioblastoma (GBM). While EGFR and EGFRvIII play critical roles in …

Glioblastoma multiforme (GBM) is a malignant primary brain tumor with a mean survival of
15 months with the current standard of care. Genetic profiling efforts have identified the …

Epidermal growth factor receptor: a re-emerging target in gl... : Current Opinion in Neurology
Epidermal growth factor receptor: a re-emerging target in glioblastoma : Current Opinion in …